|
|
|
|
| LEADER |
01822 am a22003013u 4500 |
| 001 |
110919 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Reichmuth, Andreas Michael
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemical Engineering
|e contributor
|
| 100 |
1 |
0 |
|a Langer, Robert S.
|e contributor
|
| 100 |
1 |
0 |
|a Reichmuth, Andreas Michael
|e contributor
|
| 100 |
1 |
0 |
|a Oberli, Matthias
|e contributor
|
| 100 |
1 |
0 |
|a Jaklenec, Ana
|e contributor
|
| 100 |
1 |
0 |
|a Langer, Robert S
|e contributor
|
| 100 |
1 |
0 |
|a Blankschtein, Edmundo D
|e contributor
|
| 700 |
1 |
0 |
|a Oberli, Matthias
|e author
|
| 700 |
1 |
0 |
|a Jaklenec, Ana
|e author
|
| 700 |
1 |
0 |
|a Langer, Robert S
|e author
|
| 700 |
1 |
0 |
|a Blankschtein, Daniel
|e author
|
| 245 |
0 |
0 |
|a mRNA vaccine delivery using lipid nanoparticles
|
| 260 |
|
|
|b Future Science, LTD,
|c 2017-08-03T14:33:25Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/110919
|
| 520 |
|
|
|a mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells. mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy applications, but also have great potential as prophylactic vaccines. Efficient delivery of mRNA vaccines will be key for their success and translation to the clinic. Among potential nonviral vectors, lipid nanoparticles are particularly promising. Indeed, lipid nanoparticles can be synthesized with relative ease in a scalable manner, protect the mRNA against degradation, facilitate endosomal escape, can be targeted to the desired cell type by surface decoration with ligands, and as needed, can be codelivered with adjuvants.
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (EB 000244)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Therapeutic Delivery
|
